carryover effect in endogenous substances [Regulatives / Guidelines]

posted by Ramesh Ramalingam  – India, 2018-08-08 07:29 (1007 d 01:00 ago) – Posting: # 19159
Views: 2,131

Dear Helmut,

As per previous discussion. We con't directly assess the carry-over effect for endogenous substances. As per USFDA regulatory requirement we have to approach the concept of 5% cmax for endogenous substances also https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM234960.pdf. but they are not clearly telling about how to approach these concept for endogenous substances.

Kindly share your suggestions about to below statements.
When dealing with endogenous substances, the presence of carry-over effects is very difficult to quantify. Therefore to find a proof of absence or presence of carryover effect in endogenous substances, the pre-dose (baseline) drug concentrations for Period 1 should compared to the pre-dose concentrations for Period 2. Thus, previous period average pre-dose concentration should be subtracted with subsequent period average pre-dose concentration after that the resulted values should compare with 5% of cmax. Based on this we can ensure the carry over effect occurred or not in period 1 or in subsequent period.


Regards,
Ramesh.R

Complete thread:

Activity
 Admin contact
21,446 posts in 4,483 threads, 1,511 registered users;
online 17 (1 registered, 16 guests [including 8 identified bots]).
Forum time: Tuesday 08:30 CEST (Europe/Vienna)

The fact that some geniuses were laughed at
does not imply that all who are laughed at are geniuses.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5